Join Growin Stock Community!
Back to PFE.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

cash-and-debt-chart

PFE Cash & Debt

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q3'25 (2025-09-28), Pfizer's cash and short-term investments stand at USD 14.98B, while total debt is USD 61.71B. This marks a continued gap between cash reserves and debt levels, with debt remaining significantly higher than cash holdings in the latest reported quarter. From Q1'23 to Q3'25, the chart shows that Pfizer's cash and short-term investments experienced notable volatility, peaking at USD 44.79B in Q2'23 before declining sharply to a low of USD 7.10B in Q2'24 and partially recovering thereafter. In contrast, debt levels spiked to USD 71.89B in Q4'23 and have gradually decreased over subsequent quarters, though they remain elevated. The persistent disparity between cash and debt highlights ongoing balance sheet pressure throughout the period.